Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

In November 2024, Idorsia outlined 270 positions worldwide that were at risk of redundancy to curb R&D activity. The insomnia treatment Quviviq (daridorexant) is the company’s top-selling drug ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...

Idorsia Ltd (SIX: IDIA) today announced the publication of“A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research.

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...